Cancer Institute A national cancer institute
designated cancer center

Ginna G. Laport

Publication Details

  • Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma JOURNAL OF CLINICAL ONCOLOGY Smith, S. M., Burns, L. J., Van Besien, K., LeRademacher, J., He, W., Fenske, T. S., Suzuki, R., Hsu, J. W., Schouten, H. C., Hale, G. A., Holmberg, L. A., Sureda, A., Freytes, C. O., Maziarz, R. T., Inwards, D. J., Gale, R. P., Gross, T. G., Cairo, M. S., Costa, L. J., Lazarus, H. M., Wiernik, P. H., Maharaj, D., Laport, G. G., Montoto, S., Hari, P. N. 2013; 31 (25): 3100-?


    To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma.Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n = 115; median age, 43 years) or allogeneic HCT (alloHCT; n = 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes.AutoHCT recipients were more likely in first complete remission (CR1; 35% v 14%; P = .001) and with chemotherapy-sensitive disease (86% v 60%; P < .001), anaplastic large-cell histology (53% v 40%; P = .04), and two or fewer lines of prior therapy (65% v 44%; P < .001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42% and 53%, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31% remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95% CI, 1.80 to 6.99; P < .001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95% CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95% CI, 2.15 to 11.72) were prognostic of survival.These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.

    View details for DOI 10.1200/JCO.2012.46.0188

    View details for Web of Science ID 000330540600011

    View details for PubMedID 23897963

Stanford Medicine Resources:

Footer Links: